David Sourdive
Founder bei CELLECTIS S.A.
Vermögen: 3 Mio $ am 31.03.2024
Profil
David J.
Sourdive is the founder.
He founded Cellectis SA in 1999 and holds the title of Director & Executive VP-CMC & Manufacturing.
Dr. Sourdive is also the founder of Bilhi Genetics SAS.
Dr. Sourdive's current job(s) include being the Chairman of Mablink Bioscience SAS, a Director at Exeliom Biosciences, a Director at Cell-Easy SAS since 2021, and a Venture Partner at Elaia Partners SAS since 2019.
Dr. Sourdive's former job(s) include being the Chairman & Chief Executive Officer of Takara Bio Europe AB, the President & Chief Executive Officer of Ectycell SASU from 2009 to 2012, and a Director at Medicen Paris Region, Cellectis AB, Département de la Seine-Saint-Denis (France), Mediterranean Institute For Life Sciences, EnobraQ SAS from 2018 to 2021, Eukarys SAS from 2015 to 2019, and Omics SAS from 2017 to 2020.
Dr. Sourdive's education history includes studying at Ecole Polytechnique as an undergraduate.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CELLECTIS SA
1,37% | 14.02.2023 | 983 035 ( 1,37% ) | 3 Mio $ | 31.03.2024 |
Aktive Positionen von David Sourdive
| Unternehmen | Position | Beginn |
|---|---|---|
| CELLECTIS S.A. | Founder | 20.12.1999 |
Bilhi Genetics SAS
 Bilhi Genetics SAS Pharmaceuticals: OtherHealth Technology Bilhi Genetics SAS specializes in the development of predictive medicines. It offers products for hepatic fibrosis and skin scars. The company was founded by David Sourdive and Pierre Dessein in June 2012 and is headquartered in Marseille, France. | Founder | - |
Elaia Partners SAS
 Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | Private Equity Investor | 18.12.2019 |
Cell-Easy SAS
 Cell-Easy SAS Miscellaneous Commercial ServicesCommercial Services Cell-Easy SAS operates as a stem cell contract development and manufacturing organization. It offers ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical drug development projects. The company is headquartered in Toulouse, France. | Director/Board Member | 01.02.2021 |
Mablink Bioscience
 Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | Chairman | - |
Exeliom Biosciences
 Exeliom Biosciences BiotechnologyHealth Technology Nextbiotix SAS operates as clinical-stage Biopharmaceutical Company, which develops probiotics. The company was founded by Benjamin Hadida, Harry Sokol, Philippe Langella and Patrick Gervais in 2016 and is headquartered in Dijon, France. | Director/Board Member | - |
Ehemalige bekannte Positionen von David Sourdive
| Unternehmen | Position | Ende |
|---|---|---|
EnobraQ SAS
 EnobraQ SAS Chemicals: Major DiversifiedProcess Industries EnobraQ SAS develops yeast for the production of chemical compounds. The company was founded on November 13, 2015 and is headquartered in Ramonville-Saint-Agne, France. | Director/Board Member | 01.12.2021 |
| Omics SAS | Director/Board Member | 01.05.2020 |
| Eukarys SAS | Director/Board Member | 01.12.2019 |
| ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Ausbildung von David Sourdive
| Ecole Polytechnique | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CELLECTIS S.A. | Health Technology |
| Private Unternehmen | 14 |
|---|---|
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | Finance |
Takara Bio Europe AB
 Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Commercial Services |
Ectycell SASU
 Ectycell SASU BiotechnologyHealth Technology Ectycell SASU produces and sales stem cells. It offers pluripotent stem cells that can be used to develop drugs and model diseases. The company was founded in September 2009 and is headquartered in Romainville, France. | Health Technology |
Medicen Paris Region
 Medicen Paris Region Hospital/Nursing ManagementHealth Services Medicen Paris Region is a health competitiveness cluster based in the Île-de-France region. The French company aims to promote local industrialization and respond to health sovereignty challenges. The non-profit company offers various job opportunities that can be found on their website. | Health Services |
Cellectis AB
 Cellectis AB BiotechnologyHealth Technology Part of Takara Holdings, Inc., Cellectis AB is a Swedish company that manufactures and distributes stem cell-related products. The private company is based in Gothenburg, Sweden. Cellectis was acquired by Takara Bio, Inc. from Cellectis SA on September 04, 2014. | Health Technology |
| Département de la Seine-Saint-Denis (France) | Government |
| Mediterranean Institute For Life Sciences | |
Bilhi Genetics SAS
Bilhi Genetics SAS Pharmaceuticals: OtherHealth Technology Bilhi Genetics SAS specializes in the development of predictive medicines. It offers products for hepatic fibrosis and skin scars. The company was founded by David Sourdive and Pierre Dessein in June 2012 and is headquartered in Marseille, France. | Health Technology |
EnobraQ SAS
EnobraQ SAS Chemicals: Major DiversifiedProcess Industries EnobraQ SAS develops yeast for the production of chemical compounds. The company was founded on November 13, 2015 and is headquartered in Ramonville-Saint-Agne, France. | Process Industries |
| Eukarys SAS | |
Exeliom Biosciences
Exeliom Biosciences BiotechnologyHealth Technology Nextbiotix SAS operates as clinical-stage Biopharmaceutical Company, which develops probiotics. The company was founded by Benjamin Hadida, Harry Sokol, Philippe Langella and Patrick Gervais in 2016 and is headquartered in Dijon, France. | Health Technology |
Cell-Easy SAS
Cell-Easy SAS Miscellaneous Commercial ServicesCommercial Services Cell-Easy SAS operates as a stem cell contract development and manufacturing organization. It offers ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical drug development projects. The company is headquartered in Toulouse, France. | Commercial Services |
| Omics SAS | |
Mablink Bioscience
Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | Health Technology |
